Orchestra BioMed OBIO 深 沪
已收盘 08-28 16:00:00 美东时间
5.185
+0.075
+1.47%
华盛通- 最 高5.23
- 今 开5.23
- 成交量 15.45万股
- 最 低 5.06
- 昨 收 5.11
- 总市值 3.12亿
- 52周最高 5.78
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 2.20
- 委 比 -47.26%
- 总股本 6010.50万
- 历史最高 23.39
- 量 比 0.59
- 振 幅 3.33%
- 历史最低 2.20
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 医药股AMLX飙升63%，全球首创GLP-1R拮抗剂三期临床试验成功；WEAV劲升31%
医药股AMLX飙升63%，全球首创GLP-1R拮抗剂三期临床试验成功；WEAV劲升31%，获私募巨头溢价34%收购；CDNL升逾15%，高管近日增持320万美元股份>>
08-19 16:11
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
08-11 21:16
Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 24 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $88.000 th...
08-11 05:21
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10
B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
05-20 03:44
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.41) by 19.51 percent. This is a 32.65 percent increase over losses of $(0.49) per share
05-13 04:30
Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global
05-12 20:33
